Lantheus Holdings Inc (NASDAQ:LNTH) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totalling 666,888 shares, a drop of 25.7% from the April 30th total of 897,426 shares. Based on an average daily trading volume, of 522,577 shares, the short-interest ratio is presently 1.3 days. Currently, 1.8% of the company’s stock are sold short.

In related news, insider Michael P. Duffy sold 27,313 shares of the firm’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $15.30, for a total transaction of $417,888.90. Following the transaction, the insider now directly owns 191,472 shares of the company’s stock, valued at $2,929,521.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Cesare Orlandi sold 4,194 shares of the firm’s stock in a transaction dated Thursday, April 26th. The shares were sold at an average price of $18.00, for a total transaction of $75,492.00. Following the transaction, the insider now directly owns 108,311 shares in the company, valued at $1,949,598. The disclosure for this sale can be found here. Insiders sold 40,308 shares of company stock worth $651,799 over the last ninety days. Insiders own 1.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Bank of Montreal Can raised its position in Lantheus by 371.6% in the fourth quarter. Bank of Montreal Can now owns 6,819 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 5,373 shares during the period. Financial Gravity Companies Inc. purchased a new position in shares of Lantheus in the fourth quarter worth about $158,000. Teacher Retirement System of Texas purchased a new position in shares of Lantheus in the fourth quarter worth about $200,000. AMP Capital Investors Ltd purchased a new position in shares of Lantheus in the fourth quarter worth about $205,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Lantheus in the fourth quarter worth about $267,000. 92.50% of the stock is currently owned by institutional investors and hedge funds.

LNTH stock traded down $0.35 during mid-day trading on Thursday, hitting $14.25. The company had a trading volume of 389,057 shares, compared to its average volume of 399,523. The firm has a market cap of $562.72 million, a price-to-earnings ratio of 14.25, a P/E/G ratio of 1.43 and a beta of 1.37. The company has a debt-to-equity ratio of 7.87, a quick ratio of 2.80 and a current ratio of 3.51. Lantheus has a 12 month low of $13.55 and a 12 month high of $24.45.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.22 EPS for the quarter, hitting the consensus estimate of $0.22. The business had revenue of $82.63 million for the quarter, compared to analyst estimates of $81.15 million. Lantheus had a net margin of 38.32% and a negative return on equity of 145.14%. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 earnings per share. analysts forecast that Lantheus will post 0.86 earnings per share for the current year.

A number of research firms recently weighed in on LNTH. ValuEngine lowered shares of Lantheus from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. TheStreet raised shares of Lantheus from a “d” rating to a “c-” rating in a research report on Monday, March 19th. Zacks Investment Research raised shares of Lantheus from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, BidaskClub raised shares of Lantheus from a “sell” rating to a “hold” rating in a research report on Wednesday, March 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $24.75.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.